View in EDS HTML Full Text PDF Full Text

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.

Saved in:
Bibliographic Details
Title: Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
Authors: de Botton, Stéphane1 (AUTHOR) Stephane.DEBOTTON@gustaveroussy.fr, Brandwein, Joseph M.2 (AUTHOR), Wei, Andrew H.3 (AUTHOR), Pigneux, Arnaud4 (AUTHOR), Quesnel, Bruno5 (AUTHOR), Thomas, Xavier6 (AUTHOR), Legrand, Ollivier7 (AUTHOR), Recher, Christian8 (AUTHOR), Chantepie, Sylvain9 (AUTHOR), Hunault‐Berger, Mathilde10 (AUTHOR), Boissel, Nicolas11 (AUTHOR), Nehme, Salem A.12 (AUTHOR), Frattini, Mark G.13 (AUTHOR), Tosolini, Alessandra13 (AUTHOR), Marion‐Gallois, Roland13 (AUTHOR), Wang, Jixian J.13 (AUTHOR), Cameron, Chris14 (AUTHOR), Siddiqui, Muhaimen14 (AUTHOR), Hutton, Brian15 (AUTHOR), Milkovich, Gary16 (AUTHOR)
Source: Cancer Medicine. Sep2021, Vol. 10 Issue 18, p6336-6343. 8p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20457634
DOI:10.1002/cam4.4182